MedTrace Logo

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

NCT04580420 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-12-24

No results posted yet for this study

Summary

The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

Conditions

Interventions

DRUG

DCR-PHXC

Monthly dosing throughout study period

Sponsors & Collaborators

  • Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

    lead INDUSTRY

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2031-12-30
Completion
2032-01-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Italy
  • Lebanon
  • Morocco
  • Romania
  • Spain
  • United Arab Emirates
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04580420 on ClinicalTrials.gov